Company profile
CAN-FITE BIOPHARMA LTD.
AMEX:CANFBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NAMODENOSON | phase3 | — | 7 | active |
| PICLIDENOSON | phase3 | — | 15 | completed, not_yet_recruiting, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (22)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00790218 | phase1_2 | completed | 2009-02-01 | 2012-12-01 | Can-Fite BioPharma | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma |
| NCT00790673 | phase1_2 | completed | 2009-07-01 | 2011-06-01 | Can-Fite BioPharma | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 |
| NCT06643260 | phase3 | not_yet_recruiting | 2025-06-01 | 2027-12-01 | Can-Fite BioPharma | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy |
| NCT00837291 | phase2 | withdrawn | 2018-11-01 | 2018-12-01 | Can-Fite BioPharma | A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee |
| NCT02927314 | phase2 | completed | 2017-11-27 | 2020-03-01 | Can-Fite BioPharma | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease |
FDA applications (0)
No records yet.